Core Viewpoint - Abbott has completed the acquisition of Exact Sciences, positioning itself as a leader in the rapidly growing cancer screening and diagnostics market, thereby expanding its ability to serve millions more people [1][2][8]. Group 1: Acquisition Details - The acquisition of Exact Sciences has made it a wholly owned subsidiary of Abbott, with the last trading day for Exact Sciences shares on Nasdaq being March 20, 2026 [2]. - This strategic move is expected to enhance Abbott's operational and commercial capabilities in cancer care, leveraging Exact Sciences' expertise [2][3]. Group 2: Strategic Fit - The transaction allows Abbott to advance its diagnostics offerings, focusing on preventative, predictive, and personalized healthcare solutions in response to the rising global cancer incidence [3]. - Abbott aims to establish leadership in the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical to its existing high-single-digit growth expectations [3]. Group 3: Product Offerings and Pipeline - Abbott now possesses a comprehensive suite of cancer detection products, including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard®, which are designed for early detection and personalized treatment [4][5]. - The company is also enhancing its pipeline with next-generation cancer screening technologies aimed at earlier detection and better disease management [5].

Core Insights - Abbott Laboratories has agreed to acquire Exact Sciences for $21 billion, marking a significant move in the healthcare sector focused on cancer screening [1][7] - The acquisition is aimed at expanding Abbott's diagnostics business, which has seen growth during the pandemic due to increased demand for testing [3][4] - Exact Sciences reported a record $851 million in third-quarter revenue, highlighting the potential of the cancer screening market, which Abbott estimates to be worth $60 billion in the U.S. [3][4] Company Overview - Abbott Laboratories, founded in the 1880s, is a multinational healthcare company with $42 billion in sales last year, primarily from medical devices [2] - The company has a smaller diagnostics division that it aims to expand, particularly in the cancer screening segment [3] Market Context - The healthcare sector has experienced a surge in mergers and acquisitions, with Abbott's deal being the largest since Pfizer's acquisition of Seagen for $43 billion in 2023 [5][7] - Exact Sciences shareholders will receive $105 per share, representing a 50% premium from the closing price before the acquisition news [7]